First Biosimilar Reviews Raise Questions About Differences In Asia
This article was originally published in PharmAsia News
Executive Summary
Regulators are beginning to decide on the acceptability of imitation biotech products, despite a continuing inability to fully ascertain how they differ from the brand products, or what the perceived differences actually mean